8-K: Sensus Healthcare Reports Strong Third Quarter 2024 Results, Revenue More Than Doubles

Sensus Healthcare's third quarter 2024 revenue more than doubled compared to the same period last year, reaching $8.8 million, with adjusted EBITDA also turning positive.

Summary

• Sensus Healthcare announced its financial results for the third quarter of 2024, showing significant growth.
• Revenues for the quarter reached $8.8 million, a 127% increase compared to $3.9 million in the third quarter of 2023.
• The company shipped 27 systems in the quarter, including one international sale, compared to 11 systems in the same quarter last year.
• Net income for the quarter was $1.2 million, or $0.07 per diluted share, a significant improvement from a net loss of $1.5 million, or $0.09 per share, in the prior year.
• Adjusted EBITDA was $1.6 million, compared to a negative $1.7 million in the third quarter of 2023.
• The company expects to have more than 50 IG-SRT systems signed under the Fair Deal Agreement recurring-revenue program by the end of the year.
• For the nine months ended September 30, 2024, revenues were $28.7 million, a 143% increase compared to $11.8 million in the same period of 2023.
• Net income for the nine-month period was $5.1 million, or $0.31 per diluted share, compared to a net loss of $3.7 million, or $0.23 per share, in the prior year.
• Adjusted EBITDA for the nine-month period was $6.7 million, compared to a negative $5.4 million in the same period of 2023.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong financial results, significant revenue growth, and the success of the Fair Deal Agreement program. The company's outlook is also optimistic, with expectations for continued growth and recurring revenue.

Positives

• Sensus Healthcare experienced substantial revenue growth, more than doubling year-over-year for the second consecutive quarter.
• The company achieved profitability in the third quarter, with a net income of $1.2 million.
• The Fair Deal Agreement program is gaining traction, with 22 agreements signed since its launch in March.
• The company has a strong cash position of $22.6 million and no debt.
• Gross profit margins improved to 59.3% in Q3 2024 from 51.0% in Q3 2023.
• The company is seeing increased interest in non-melanoma skin cancer treatment.
• The company's proprietary software, Sentinel IT, is considered a valuable asset.

Negatives

• Accounts receivable increased to $17.0 million as of September 30, 2024, compared to $10.6 million as of December 31, 2023, due to increased sales and extended payment terms with a large customer.
• General and administrative expenses increased slightly due to higher compensation and bad debt expense.

Risks

• The company's ability to maintain profitability is a risk factor.
• The company's ability to sell the anticipated number of SRT units for the remainder of 2024 is a risk.
• Inflationary pressures could impact sales.
• Changes in government or third-party payor reimbursement for procedures using their products could affect sales.
• Regulatory requirements and the ability to manage manufacturing processes and costs are ongoing risks.
• The company faces risks from doing business in China and other foreign countries.
• The company has a concentration of customers in the U.S. and China, including a concentration of sales to one particular customer in the U.S.
• The performance of the company's information technology systems and its ability to maintain data security are risks.
• The company's ability to obtain and maintain intellectual property rights is a risk.

Future Outlook

The company expects to have more than 50 IG-SRT systems signed under the Fair Deal Agreement by the end of 2024 and anticipates generating recurring revenue from these systems in 2025. They also expect the Fair Deal model to contribute to growth for years to come due to the growing utilization of SRT for non-melanoma skin cancer and keloid scars.

Management Comments

• Joe Sardano, chairman and chief executive officer, stated that the company's revenues more than doubled year-over-year for the second consecutive quarter and they maintained profitability despite summer seasonality.
• Mr. Sardano noted that the revenue-sharing Fair Deal Agreement continues to attract significant attention.
• Mr. Sardano added that they have exceeded their goal of having up to 50 Fair Deal Agreements signed by the end of 2024.
• Mr. Sardano believes that the market for non-melanoma skin cancer treatments is enormous and that SRT is becoming the people's choice for treatment.

Industry Context

The announcement highlights the growing demand for non-invasive skin cancer treatments, aligning with the broader trend of patient-centric and cost-effective healthcare solutions. The company's focus on superficial radiotherapy (SRT) positions it well in a market where non-melanoma skin cancer is prevalent.

Comparison to Industry Standards

• Sensus Healthcare's revenue growth of 127% in Q3 and 143% for the nine-month period significantly outperforms many established medical device companies, which typically see single-digit or low double-digit growth.
• Companies like Accuray Incorporated (ARAY) and Varian Medical Systems (VAR) are competitors in the radiation oncology space, but they focus on more complex and expensive treatments. Sensus's focus on superficial radiotherapy for skin conditions provides a niche market with less direct competition.
• The Fair Deal Agreement model is a unique approach that differentiates Sensus from competitors who typically sell equipment outright. This model is similar to some software-as-a-service (SaaS) models, which can lead to more predictable recurring revenue streams.
• The gross profit margin of 59.3% in Q3 is competitive within the medical device industry, indicating efficient cost management. Companies like Intuitive Surgical (ISRG) have higher margins, but they operate in a different segment of the market.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and positive outlook.
• Employees may benefit from the company's growth and success.
• Customers will have access to innovative and effective treatment options.
• Suppliers may see increased demand for their products and services.
• Creditors will likely view the company as a lower credit risk due to its improved financial performance.

Next Steps

• The company expects to have more than 50 IG-SRT systems signed under the Fair Deal Agreement by the end of the year.
• The company anticipates generating recurring revenue from these systems in 2025.
• The company will continue to monitor the market for non-melanoma skin cancer treatments.

Key Dates

Keywords

Sensus Healthcare, SRT, IG-SRT, Superficial Radiotherapy, Non-Melanoma Skin Cancer, Fair Deal Agreement, Medical Devices, Financial Results, EBITDA, Revenue, Net Income